0001209191-17-059430.txt : 20171106
0001209191-17-059430.hdr.sgml : 20171106
20171106164438
ACCESSION NUMBER: 0001209191-17-059430
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171102
FILED AS OF DATE: 20171106
DATE AS OF CHANGE: 20171106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gano Kyle
CENTRAL INDEX KEY: 0001567160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 171179957
MAIL ADDRESS:
STREET 1: NEUROCRINE BIOSCIENCES, INC.
STREET 2: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-02
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001567160
Gano Kyle
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Business Development Off
Common Stock
2017-11-02
4
M
0
11350
8.65
A
84596
D
Common Stock
2017-11-02
4
S
0
11350
71.05
D
73246
D
Common Stock
2017-11-02
4
M
0
13468
8.66
A
86714
D
Common Stock
2017-11-02
4
S
0
13468
71.05
D
73246
D
Incentive Stock Option
8.65
2017-11-02
4
M
0
11350
8.65
D
2023-01-10
Common Stock
11350
0
D
Incentive Stock Option
8.66
2017-11-02
4
M
0
13468
8.66
D
2022-01-12
Common Stock
13468
0
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Option granted January 10, 2013 and vested monthly over four years.
Option granted January 12, 2012 and vested monthly over four years.
/s/ Darin Lippoldt, Attorney-in-Fact
2017-11-06